Dealership Agreement With Manner Chemical In Relation To KT-939
Recently, Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( the “Suzhou Kintor”), a wholly-owned subsidiary of the Company, entered into the personal care products dealership agreement (the “Dealership Agreement”) with the Guangzhou Wanlu Chemical Co., Ltd. ("Wanlu Chemical") and Shanghai Fangdeng Chemical Co., Ltd. ("Fangdeng Chemical") (collectively referred to as "Manner Chemical") respectively in relation to the dealership authorisations of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939 and the consensus of target sales volumes for the next three years. Pursuant to the Dealership Agreement, the Suzhou Kintor authorizes Wanlu Chemical as a dealership of KT-939 in Southern China and Southwest China, and authorizes Fangdeng Chemical as a dealership of KT-939 in Eastern China and Northern China, thus Manner Chemical being responsible for sales within the designated territory.
Manner Chemical, established in September 2002, is a leading industry enterprise specializing in the agency and sales of daily chemical raw materials, with a commitment of providing customers with comprehensive one-stop solutions encompassing formulations, framework materials, and active ingredients to meet diverse client needs. Leveraging its profound industry experience, premium products and services, and strong comprehensive capabilities, Manner Chemical was honored with the "2025 China Top 100 Cosmetic Raw Material Suppliers" award.
Manner Chemical has established a nationwide service network and serves as the authorized agent or distributor in China for USA Dow Chemical, Germany Evonik, Netherlands DSM, Germany Susonity (formerly Merck,), Belgium Oleon, USA Nouryon, France Gattefossé, and Shenzhen JYMed. With a client base of over 3,000 end users and business operations spanning provinces and cities throught country, Manner Chemical has achieved deep market penetration and strong brand influence.
The signing of the Dealership Agreement with Manner Chemical is aimed at establishing a long-term and stable strategic cooperation, thereby driving the market expansion of the functional cosmetic raw material KT-939 in the Eastern China, Northern China, Southern China and Southwest China regions. Through this collaboration, Suzhou Kintor will leverage Manner Chemical's market resources and sales channels within the designated territory to broaden the market coverage and enhance the influence of KT-939.
About Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
